Snapshot img

Type 2 Diabetes Market Size 2025-2029

The type 2 diabetes market size is forecast to increase by USD 53.8 billion at a CAGR of 12.2% between 2024 and 2029.

The market is experiencing significant growth due to several key factors. The rising prevalence of diabetes, driven by unhealthy lifestyles and an aging population, is a major growth driver. Additionally, the low diagnosis rate presents an opportunity for market expansion. It is administered via different routes, including subcutaneous injection, insulin pumps, and insulin pens. According to the American Diabetes Association, approximately 26.8 million people in the United States have diabetes, and 7.3 million are undiagnosed. With increasing awareness and advancements in diagnostic tools, this number is expected to increase. These include continuous glucose monitoring systems, closed-loop insulin delivery systems, and non-pharmacological interventions such as diet and exercise. Furthermore, the growing burden of diabetes on healthcare systems and the need for effective management solutions are creating new opportunities for market participants. Overall, the market is poised for growth in the coming years, driven by these key trends and challenges.

What will be the Size of the Type 2 Diabetes Market During the Forecast Period?

Request Free Sample

The market encompasses a range of therapeutic compounds designed to manage and mitigate the effects of this chronic condition. With a global prevalence estimated to affect over 463 million people, primarily adolescents and young adults, the market exhibits significant growth due to the increasing burden of cardiovascular diseases, renal problems, and neurological complications associated with hyperglycemia. These complications include heart diseases, damage to the kidneys, and eye disorders, among others. Insulin and non-insulin medications, such as Jardiance, Tanzeum, and Trulicity, are commonly used to regulate blood sugar levels and alleviate symptoms like increased thirst, urination, fatigue, blurred vision, slow-healing wounds, and infections. Additionally, patients may experience tingling, numbness in feet and hands, and other neurological issues. Pharmaceutical companies continue to invest in research and development to address the unmet needs of this patient population and improve overall quality of life.

How is this Type 2 Diabetes Industry segmented and which is the largest segment?

The type 2 diabetes industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Drug Class

  Insulin
  DPP-4 inhibitor
  GLP-1 receptor agonists
  SGLT-2 inhibitors
  Others


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Delivery Mode

  Oral
  Injectable
  Continuous glucose monitoring (CGM)


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Drug Class Insights

The insulin segment is estimated to witness significant growth during the forecast period.

Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and high blood glucose levels. This condition affects adolescents, teenagers, and young adults, leading to increased thirst, urination, fatigue, blurred vision, slow-healing wounds, infections, tingling, numbness in feet and hands, yeast infections, darkened skin areas, and neurological problems. Over time, high blood glucose levels can lead to cardiovascular diseases, renal problems, and damage to the eyes. Insulin, a peptide hormone, plays a crucial role in regulating blood glucose levels. It interacts with insulin receptors on cell surfaces, facilitating the absorption of glucose into the cells. Insulin deficiency or insulin resistance leads to hyperglycemia, which can result in complications. The market for therapeutic compounds to manage Type 2 diabetes includes various drug classes such as insulin, thiazolidinediones, PPAR receptors agonists, Dipeptidyl Peptidase-4 Inhibitors, Alpha-Glucosidase Inhibitors, Sulfonylureas, Secretagogues, Biguanides, and others.

Moreover, these medications help improve glycemic control, reduce cardiovascular risk, and avoid hypoglycemia. Insulin is available in various forms, including human insulin, analog insulins, and inhaled insulin. Retail pharmacies and online pharmacies offer convenience for patients to access insulin and other diabetes medications. The market for Type 2 diabetes medications is expected to grow significantly due to the increasing prevalence of the disease and the need for effective disease management. Emerging economies are expected to offer significant growth opportunities due to increasin

According to a survey conducted between 2019 and 2021 in India, about four percent each among men and women, aged 35 to 49 years reported having diabetes. During the same time period, Indians between 15 and 19 years old had the lowest prevalence of diabetes.

Snapshot img

Diabetes Management Devices Market Size 2024-2028

The diabetes management devices market size is forecast to increase by USD 13.98 bn at a CAGR of 7.68% between 2023 and 2028.

The market is witnessing significant growth due to the rising global burden of diabetes and the increasing focus on advanced technologies such as artificial pancreas systems. These systems utilize insulin pumps and continuous glucose monitoring sensors to automatically adjust insulin delivery based on real-time glucose levels. Additionally, the integration of artificial intelligence and data analytics in diabetes management devices is revolutionizing the industry, enabling remote patient monitoring and personalized treatment plans. Other trends include the development of insulin pens with advanced features and the adoption of spectroscopy technology for non-invasive blood glucose monitoring. However, the prohibitive cost of diabetes care devices remains a major challenge for market growth.Overall, the market is expected to experience robust growth In the coming years, driven by technological advancements and the increasing prevalence of diabetes.

What will be the Size of the Diabetes Management Devices Market during the Forecast Period?

Request Free SampleThe market encompasses a range of technologies designed to assist individuals in managing their diabetes, including insulin delivery devices, mobile health applications, and disease management tools. With the global diabetic population projected to reach over 592 million by 2035, driven by factors such as obesity rates, smoking, and high cholesterol levels, the market for diabetes care devices is experiencing significant growth. Hospitals and specialty clinics are increasingly adopting minimally invasive devices, such as diabetes lancet devices and diabetes tracker devices, to improve patient care and outcomes. Type 1 diabetes, an autoimmune disease characterized by insulin deficiency, and Type 2 diabetes, often associated with insulin resistance, both require ongoing management to prevent complications, including kidney failure, gangrene, and lower limb amputation.Insulin delivery devices, including insulin pens and blood glucose level monitoring systems, are essential tools in managing both types of diabetes. The market for diabetes management devices is expected to continue expanding as technology advances and the global population ages.

How is this Diabetes Management Devices Industry segmented and which is the largest segment?

The diabetes management devices industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. ProductBlood glucose monitoring devicesInsulin delivery systemsDistribution ChannelOfflineOnlineGeographyNorth AmericaUSEuropeGermanyUKFranceAsiaChinaRest of World (ROW)

By Product Insights

The blood glucose monitoring devices segment is estimated to witness significant growth during the forecast period. Diabetes management devices play a crucial role in monitoring and managing blood glucose levels for individuals with diabetes. These devices include a range of products such as insulin delivery systems, continuous monitoring systems, and glucose monitoring devices. Insulin delivery devices, including insulin pumps and pens, facilitate precise insulin administration. Continuous monitoring systems, such as continuous glucose monitoring systems (CGMs) and Mobi insulin pumps, provide real-time glucose level data through wireless transmission and dedicated apps. Glucowear, a continuous glucose monitoring system, offers non-invasive transdermal sensors and spectroscopy technology. Hospital pharmacies, retail pharmacies, and online pharmacies stock these diabetes care devices. The increasing prevalence of diabetes among the obese, elderly population, and those with conditions like high cholesterol levels, smoking, and inactive lifestyles necessitates effective diabetes management.Disease management is essential to prevent complications like kidney failure, gangrene, lower limb amputation, heart attack, blindness, and stroke. Diabetes tracker devices, such as diabetes monitoring software and artificial pancreas systems, help healthcare providers analyze glucose patterns and create treatment plans. User-friendly interfaces, visual representations, and medication adherence features enhance the efficacy of treatment. In summary, diabetes management devices, including insulin delivery devices, continuous monitoring systems, and glucose monitoring devices, are essential tools for managing diabetes and preventing complications. These devices offer precision, flexibility, and smart features, making diabetes care more accessible and convenient for individuals with diabetes. Hospital segment, diagnostic centers, diabetes clinics, and health

The global glucose tracking app market is experiencing robust growth, driven by the rising prevalence of diabetes and the increasing adoption of digital health solutions. The market, valued at approximately $1.5 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 15% from 2025 to 2033. This significant growth is fueled by several key factors. Firstly, the increasing awareness of diabetes management and the need for proactive monitoring among individuals with diabetes and prediabetes is driving demand. Secondly, the convenience and accessibility offered by these apps, allowing for remote monitoring and data sharing with healthcare providers, are proving highly attractive. Thirdly, technological advancements are continually enhancing app functionality, incorporating features like medication reminders, meal tracking, and integration with continuous glucose monitors (CGMs). The segment comprising cloud-based apps holds a dominant market share due to its flexibility and accessibility, while the personal application segment is larger than the family application segment reflecting the individual nature of diabetes management. However, challenges remain. Data privacy concerns and the need for regulatory compliance are potential restraints. Furthermore, ensuring app accuracy and reliability is crucial for user trust and adoption. Competition among existing players and the entry of new entrants are also shaping the market landscape. Future growth will likely be influenced by advancements in AI-driven analytics within the apps, personalized diabetes management programs, and greater integration with wearable devices. Geographical expansion, particularly in developing countries with high diabetes prevalence, presents significant opportunities. The market is segmented by type (cloud-based, on-premises) and application (personal, family), with significant regional variations across North America, Europe, Asia-Pacific, and other regions reflecting varying levels of technological adoption and healthcare infrastructure.

In 2022, there were 1,420 patients per 100,000 population suffering from diabetes mellitus in Thailand. The number of diabetic patients slightly declined from the previous year, which reached over 1,500 per 100,000 inhabitants in the country.

Market Overview:

United States digital diabetes management market size reached US$ 3.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 15.2 Billion by 2032, exhibiting a growth rate (CAGR) of 18.64% during 2024-2032. The rising emphasis on continuous patient engagement, along with the growing popularity of personalized healthcare, is primarily driving the market growth.

Report Attribute	Key Statistics
Base Year	2023
Forecast Years	2024-2032
Historical Years	2018-2023
Market Size in 2023	US$ 3.3 Billion
Market Forecast in 2032	US$ 15.2 Billion
Market Growth Rate (2024-2032)	18.64%

Digital diabetes management involves employing technology and digital solutions to support individuals in overseeing and regulating their diabetes condition. These digital tools and applications encompass diverse features that assist in monitoring blood glucose levels, ensuring medication adherence, tracking physical activity, and managing dietary intake. Through the utilization of smartphones, wearable devices, and cloud-based platforms, digital diabetes management enables the real-time collection and analysis of data, promoting enhanced self-management and patient engagement. A notable advantage of this approach is its capacity to deliver personalized insights and practical recommendations based on the gathered data. This empowers individuals to make well-informed decisions regarding their lifestyle and treatment choices. Moreover, healthcare providers gain access to a comprehensive overview of the patient's health, facilitating remote monitoring and timely interventions as needed. Additionally, these technologies play a pivotal role in improving patient outcomes by sustaining continuous engagement and motivation through interactive features and educational resources. They also streamline communication between patients and healthcare professionals, ultimately enhancing the overall quality of patient care.

United States Digital Diabetes Management Market Trends:

The United States digital diabetes management market is witnessing a surge in growth, driven by key drivers and emerging trends that underscore the transformative impact of technology on diabetes care. Technological advancements stand out as a primary driver, with the integration of smartphones, wearable devices, and cloud-based platforms enhancing the accessibility and effectiveness of digital diabetes management solutions. Moreover, as the number of individuals diagnosed with diabetes continues to grow, there is an increasing demand for innovative solutions that facilitate personalized and efficient self-management. Besides this, interconnectivity and data-sharing capabilities are shaping the market, enabling seamless communication between patients and healthcare providers. Additionally, remote monitoring and timely interventions are becoming standard practices, enhancing patient care and facilitating more proactive healthcare approaches. Apart from this, interactive features and educational resources embedded in these technologies play a crucial role in sustaining patient motivation and promoting long-term adherence to diabetes management plans. Furthermore, technological advancements, the increasing diabetes prevalence, and personalized healthcare approaches are expected to fuel the market growth across the country over the forecasted period.

United States Digital Diabetes Management Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on product type and device type.

Product Type Insights:

https://www.imarcgroup.com/CKEditor/7b549f7f-f20e-4e5b-94d9-5e4962272768other-regions1.webp" style="height:450px; width:800px" />

• Smart Glucose Meter
• Smart Insulin Pumps
• Smart Insulin Pens
• Apps
  

The report has provided a detailed breakup and analysis of the market based on the product type. This includes smart glucose meter, smart insulin pumps, smart insulin pens, and apps.

Device Type Insights:

• Handheld Devices
• Wearable Devices
  

A detailed breakup and analysis of the market based on the device type have also been provided in the report. This includes handheld devices and wearable devices.

Regional Insights:

https://www.imarcgroup.com/CKEditor/4b465987-57d3-4cd0-8106-e8e0bddefdd8other-regions8.webp" style="height:450px; width:800px" />

• Northeast
• Midwest
• South
• West
  

The report has also provided a comprehensive analysis of all the major regional markets, which include Northeast, Midwest, South, and West.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

United States Digital Diabetes Management Market Report Coverage:

Report Features	Details
Base Year of the Analysis	2023
Historical Period	2018-2023
Forecast Period	2024-2032
Units	US$ Billion
Scope of the Report	Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment: Product Type Device Type Region
Product Types Covered	Smart Glucose Meter, Smart Insulin Pumps, Smart Insulin Pens, Apps
Device Types Covered	Handheld Devices, Wearable Devices
Regions Covered	Northeast, Midwest, South, West
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 3699 Five User License: US$ 4699 Corporate License: US$ 5699
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report:

• How has the United States digital diabetes management market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the United States digital diabetes management market?
• What is the breakup of the United States digital diabetes management market on the basis of product

Snapshot img

Digital Diabetes Management Market Size 2024-2028

The global digital diabetes management market size is estimated to grow by USD 19.12 billion at a CAGR of 21.99% between 2023 and 2028. The digital diabetes market refers to the use of technology and digital tools in managing and monitoring diabetes. Diabetes, a chronic condition, arises when the body struggles to utilize insulin effectively or when the pancreas fails to produce adequate insulin. Elevated blood sugar levels, known as hyperglycemia, pose significant risks and can lead to severe complications if left unmanaged. The growing popularity of digital diabetes management stands as a key driver fueling market growth. Digital diabetes management can be enhanced by integrating automatic pill dispensing systems, ensuring timely medication and improving patient adherence. As diabetes prevalence escalates globally, there is an increasing demand for effective management solutions to improve patient outcomes and mitigate healthcare expenses. Digital diabetes management encompasses the utilization of technological tools such as wearables, smartphone applications, and cloud-based platforms for monitoring and managing diabetes effectively.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentations

The market is witnessing significant growth driven by advancements in technology and increasing demand for innovative solutions. Cloud-based enterprise solutions and artificial intelligence (AI) technologies are revolutionizing diabetes care by leveraging big data analytics and machine learning algorithms to provide personalized insights and predictions for patients. Smart insulin pens and wearable medical devices enable convenient insulin monitoring and blood glucose monitoring systems, empowering patients to manage their condition effectively. Healthcare providers benefit from AI-driven solutions that offer exercise guidance and closed-loop pumps, enhancing treatment outcomes and patient care. With a growing geriatric population, the demand continues to rise, highlighting the importance of technological innovation in improving the lives of diabetes patients.

End-user Analysis

The market share growth by the hospitals segment will be significant during the forecast period. The hospital segment of the market refers to the use of digital tools and technology to manage and treat diabetes in a hospital setting. This segment includes various digital solutions such as mobile applications, online platforms, electronic health records (EHRs), medical devices, and telehealth services that are used by healthcare professionals and patients to manage diabetes.

Get a glance at the market contribution of various segments View a PDF Sample

The hospitals segment was valued at USD 1.77 billion in 2018. Some of the key aspects of the hospital segment in the market include remote patient monitoring, diabetes education, and self-management, electronic health records (EHRs), telehealth services, medical device integration, data analytics, and decision support. By adopting digital tools and technologies, hospitals can provide more personalized care, improve access to healthcare services, and empower patients to actively participate in their diabetes management, which will drive the growth of the market during the forecast period.

Type Analysis

Wearable devices for diabetics include continuous glucose monitoring (CGM) systems and insulin pumps, which help to manage their blood sugar levels much more effectively and easily. Wearable devices were originally developed for people with type 1 diabetes, but technological advances have expanded their use in type 2 diabetics. Moreover, growth in the number of regulatory approvals for CGM systems and the development of advanced wearable products such as closed-loop pump systems and smart insulin patches will further enhance the growth of the wearable devices segment of the market during the forecast period.

Regional Analysis

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. With the increasing incidence in the region, there is a high demand for innovative solutions to manage and monitor this disease. Additionally, the region's demand for telemedicine platforms and remote patient monitoring devices is driven by the need for remote monitoring and virtual consultations.

Furthermore, favorable government programs and regulatory frameworks are also fostering market growth. North America is home to a number of significant market participants, such as Medtronic, Dexcom, Abbott Laboratories, Insulet Corporation, and Livo

The global digital diabetes management market, valued at $11.24 billion in 2025, is projected to experience robust growth, driven by a rising prevalence of diabetes worldwide, increasing adoption of connected health technologies, and a growing demand for remote patient monitoring solutions. The market's Compound Annual Growth Rate (CAGR) of 21.99% from 2025 to 2033 indicates significant expansion potential. Key drivers include the convenience and efficacy of remote glucose monitoring, personalized treatment plans facilitated by digital platforms, and the integration of data analytics for improved disease management. Technological advancements, such as the development of more accurate and user-friendly continuous glucose monitors (CGMs) and insulin pumps, are further fueling market growth. Furthermore, increased healthcare expenditure and supportive government initiatives aimed at improving diabetes care are contributing factors. The market is segmented by type (CGMs, insulin pumps, mobile apps, software platforms) and application (type 1 diabetes, type 2 diabetes, gestational diabetes), with each segment demonstrating varying growth trajectories influenced by factors like technological maturity, cost-effectiveness, and patient preference. Competitive forces are shaping the market landscape, with established players like Abbott Laboratories and Medtronic, alongside innovative startups, vying for market share. Future growth will depend on factors like the successful integration of artificial intelligence in diabetes management, advancements in closed-loop insulin delivery systems, and the widening accessibility and affordability of digital health tools. The market's regional distribution reflects global diabetes prevalence patterns, with North America and Europe currently holding the largest market shares due to high diabetes rates and advanced healthcare infrastructure. However, rapidly growing economies in Asia-Pacific, particularly India and China, are poised to witness significant growth in the digital diabetes management market in the coming years. Challenges include data security and privacy concerns, the digital literacy gap amongst certain patient populations, and regulatory hurdles related to the approval and reimbursement of digital health technologies. However, ongoing efforts to address these challenges, coupled with sustained technological innovation and the increasing recognition of the benefits of digital diabetes management, suggest a promising future for this market.

The online diabetes counseling market is experiencing robust growth, driven by increasing prevalence of diabetes, rising adoption of telehealth, and the convenience and accessibility offered by virtual counseling. The market size in 2025 is estimated at $2.5 billion, exhibiting a Compound Annual Growth Rate (CAGR) of 15% from 2025 to 2033. This significant expansion is fueled by several key factors. Firstly, the global surge in diabetes cases necessitates innovative and accessible management strategies. Online counseling provides a scalable and cost-effective solution compared to traditional in-person consultations, particularly beneficial in underserved or geographically remote areas. Secondly, the increasing comfort and trust in telehealth platforms, accelerated by the recent pandemic, are further boosting market adoption. Patients appreciate the flexibility of scheduling sessions at their convenience and the reduced travel time and expenses associated with virtual consultations. Thirdly, the integration of technology, including remote monitoring devices and mobile applications, enhances the effectiveness of online counseling by enabling personalized feedback and proactive management of diabetes. Technological advancements in personalized medicine and data analytics will continue to refine the services offered, ultimately improving patient outcomes and further driving market expansion. The market segmentation reveals significant opportunities across various categories. While self/home healthcare currently dominates the application segment, the hospitals & specialty diabetes clinics segment holds immense growth potential due to collaborations and integration into existing healthcare infrastructure. The blood sugar management segment is the largest type of online diabetes counseling, reflecting the critical need for focused support in this area. However, other segments, such as exercising and diet & nutrition counseling, are also gaining traction as patients recognize the holistic nature of diabetes management. Geographically, North America and Europe currently hold the largest market share, but significant growth is anticipated in Asia Pacific, driven by rising diabetes prevalence and increasing healthcare expenditure in rapidly developing economies. The competitive landscape is characterized by a mix of established healthcare companies and innovative technology providers, constantly striving to enhance service offerings and expand their market reach. The market’s future trajectory remains positive, with ongoing technological advancements and growing awareness of the benefits of online diabetes counseling expected to fuel continued growth throughout the forecast period.

This dataset is about news and is filtered where the news includes Diabetes . It has 8 columns such as classification, entities, news, news link, and publication date. The data is ordered by publication date (descending).

Background and aimsSince Type 1 Diabetes (T1D) onset usually occurs at a young age, a relevant number of affected people attend school for most of their time; it is necessary that school personnel receive appropriate education and training. We aimed to evaluate the effectiveness of the online training program offered by IRCCS Istituto Giannina Gaslini during and after COVID-19 pandemic.MethodsThe Institute’s Diabetes team offered an online training program to school staff of the Region during COVID-19 pandemic. A validated questionnaire was proposed to all the schools in which training meetings were held in the previous 2 years (2020–2021 and 2021–2022). The questionnaire consisted of four sections: Section 1 (Socio-demographical data), Section 2 (Theoretical knowledge on T1D), Section 3 (Confidence in handling T1D), and Section 4 (Practical skills and Glucagon Administration). To evaluate the effectiveness of the online training program, the answers between participants (Group A) and non-participants (Group B) were then compared.Results225 subjects from 19 schools participated in the survey. People who participated to the training (Group A, n = 53) demonstrated better T1D theoretical knowledge compared to non-participants (Group B, n = 154; p 

Market Overview:

Vietnam oral anti diabetic drug market size is projected to exhibit a growth rate (CAGR) of 3.56% during 2024-2032. The rising prevalence of diabetes, the introduction of a diverse range of oral anti-diabetic drugs, the rapid expansion of healthcare facilities and the easy availability of skilled healthcare professionals represent some of the key factors driving the market.

Report Attribute	Key Statistics
Base Year	2023
Forecast Years	2024-2032
Historical Years	2018-2023
Market Growth Rate (2024-2032)	3.56%

Oral anti-diabetic drugs are pharmaceutical medications designed to manage and control high blood sugar levels in individuals with diabetes mellitus. These drugs are taken orally, typically in the form of tablets or capsules, and work by various mechanisms to help regulate blood glucose levels. They are an essential component of diabetes management, often used alongside lifestyle modifications and insulin therapy. The primary goal of oral anti-diabetic drugs is to lower blood sugar levels within a healthy range, thus reducing the risk of complications associated with diabetes, such as cardiovascular disease, kidney problems, and nerve damage. These medications work in different ways, including stimulating insulin production, increasing insulin sensitivity in cells, or slowing down the absorption of glucose from the digestive tract. It is crucial for individuals with diabetes to work closely with healthcare professionals to determine the most suitable oral anti-diabetic drug(s) based on their specific needs and medical history. Regular monitoring of blood glucose levels and adherence to prescribed medication regimens are essential to achieve effective diabetes management and maintain overall health.

Vietnam Oral Anti Diabetic Drug Market Trends:

The rising prevalence of diabetes among the masses due to changes in lifestyle, dietary habits, and an aging population is driving the global market. This has created a substantial patient pool in need of oral anti-diabetic medications, thereby impelling the market. Moreover, government initiatives have also played a crucial role in catalyzing this market. The Vietnamese government has taken steps to improve healthcare access and affordability, including providing support for diabetes management programs. This has made oral anti-diabetic drugs more accessible to a broader segment of the population. Furthermore, pharmaceutical companies operating in Vietnam have been actively introducing and promoting innovative oral anti-diabetic drugs. These companies are investing heavily in research and development (R&D) activities to bring new, more effective medications to the market, which is acting as a significant growth-inducing factor. Apart from this, the easy availability of a diverse range of oral anti-diabetic drugs with varying mechanisms of action has provided healthcare professionals with more treatment options, which in turn is increasing the overall market demand. Besides this, the heightened awareness about diabetes and its management has played a pivotal role. Health campaigns and educational efforts have helped inform the public about the importance of early diagnosis and treatment of diabetes, thereby leading to a higher demand for oral anti-diabetic drugs as part of diabetes management. Additionally, healthcare infrastructure improvements have made it easier for patients to access healthcare services, including diabetes diagnosis and treatment, which is fueling the market. The expansion of healthcare facilities and the rising number of skilled healthcare professionals are also contributing to the growth of the oral anti-diabetic drug market.

Vietnam Oral Anti Diabetic Drug Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on oral anti-diabetic drugs.

Oral Anti-Diabetic Drugs Insights:

https://www.imarcgroup.com/CKEditor/536a9dba-1260-4cc0-b5d1-5d068f061661vietnam-oral-anti-diabetic-drug-market-sagment.webp" style="height:450px; width:800px" />

• Biguanides
• Alpha-Glucosidase Inhibitors
• Dopamine D2 Receptor Agonist
• SGLT-2 Inhibitors
  • Invokana (Canagliflozin)
  • Jardiance (Empagliflozin)
  • Farxiga/Forxiga (Dapagliflozin)
  • Suglat (Ipragliflozin)
• DPP-4 Inhibitors
  • Onglyza (Saxagliptin)
  • Tradjenta (Linagliptin)
  • Vipidia/Nesina (Alogliptin)
  • Galvus (Vildagliptin)
• Sulfonylureas
• Meglitinides
  

The report has provided a detailed breakup and analysis of the market based on the oral anti-diabetic drugs. This includes biguanides, alpha-glucosidase inhibitors, dopamine d2 receptor agonist, sglt-2 inhibitors {(invokana (canagliflozin), jardiance (empagliflozin), farxiga/forxiga (dapagliflozin), suglat (ipragliflozin)}, dpp-4 inhibitors {(onglyza (saxagliptin), tradjenta (linagliptin), vipidia/nesina (alogliptin), galvus (vildagliptin)}, sulfonylureas, and meglitinides.

Regional Insights:

https://www.imarcgroup.com/CKEditor/06ba01cd-2c1f-4d95-8c72-f4b964e52d66vietnam-oral-anti-diabetic-drug-market-regional.webp" style="height:450px; width:800px" />

• Northern Vietnam
• Central Vietnam
• Southern Vietnam
  

The report has also provided a comprehensive analysis of all the major regional markets, which include Northern Vietnam, Central Vietnam, and Southern Vietnam.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Vietnam Oral Anti Diabetic Drug Market Report Coverage:

Report Features	Details
Base Year of the Analysis	2023
Historical Period	2018-2023
Forecast Period	2024-2032
Units	US$ Million
Scope of the Report	Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment: Oral Anti-Diabetic Drugs Region
Oral Anti-Diabetic Drugs Covered	Biguanides Alpha-Glucosidase Inhibitors Dopamine D2 Receptor Agonist SGLT-2 Inhibitors: Invokana (Canagliflozin), Jardiance (Empagliflozin), Farxiga/Forxiga (Dapagliflozin), Suglat (Ipragliflozin) DPP-4 Inhibitors: Onglyza (Saxagliptin), Tradjenta (Linagliptin), Vipidia/Nesina (Alogliptin), Galvus (Vildagliptin) Sulfonylureas Meglitinides
Regions Covered	Northern Vietnam, Central Vietnam, Southern Vietnam
Customization Scope	10% Free Customization
Report Price and

Pet Diabetes Care Market Outlook

The global pet diabetes care market size was valued at approximately USD 1.2 billion in 2023 and is projected to reach around USD 2.5 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.1% during the forecast period. The rising prevalence of diabetes among pets, increasing pet ownership, and growing awareness about pet health are key factors driving market growth. The demand for advanced diabetes care products and solutions for pets has been on the rise, contributing significantly to market expansion.

One of the major growth factors of the pet diabetes care market is the increasing incidence of diabetes among pets. Just as in humans, lifestyle factors and genetic predispositions are leading to a rise in diabetes cases among pets, particularly dogs and cats. This has led to a surge in demand for effective diabetes management solutions, including insulin delivery devices, glucose monitoring systems, and veterinary insulin. Owners are more willing to invest in advanced healthcare solutions to ensure the well-being of their pets, thereby driving market growth.

The growing awareness and importance of pet health are also crucial contributors to the market's growth. Pet owners today are more informed about the health risks associated with untreated diabetes in pets. Awareness campaigns and educational initiatives by veterinary associations and pet care companies have played a significant role in this regard. This increased awareness has translated into higher adoption rates of diabetes management products and services for pets, further bolstering market growth.

Technological advancements in pet diabetes care devices are another significant growth driver. Innovations such as continuous glucose monitoring systems, smart insulin delivery devices, and tele-veterinary services have made it easier for pet owners to manage their pets’ diabetes. These technologies offer more precise and less invasive ways to monitor and control blood sugar levels, improving the quality of life for diabetic pets. The convenience and accuracy provided by these advanced devices have led to higher adoption rates, positively impacting the market.

Regionally, North America dominates the pet diabetes care market due to high pet ownership rates and advanced veterinary healthcare infrastructure. The United States, in particular, has a significant share of the market, with many pet owners willing to spend on sophisticated healthcare for their pets. Europe follows closely, driven by similar factors. The Asia Pacific region is expected to witness the highest growth rate during the forecast period, owing to increasing disposable income, growing pet adoption, and rising awareness about pet health in emerging economies such as China and India.

Product Type Analysis

Insulin delivery devices form a crucial segment in the pet diabetes care market, encompassing products like insulin pens, syringes, and pumps. These devices are essential for administering the correct insulin dosage to diabetic pets. The convenience and precision offered by modern insulin delivery devices have made them increasingly popular among pet owners. Technological advancements, such as needle-free insulin delivery systems, have further enhanced the user experience, encouraging more pet owners to adopt these products for managing their pets' diabetes.

Glucose monitoring devices are another vital segment, including traditional blood glucose meters and continuous glucose monitoring (CGM) systems. These devices help pet owners and veterinarians monitor the blood sugar levels of diabetic pets effectively. CGM systems, in particular, have gained traction due to their ability to provide real-time glucose level data without requiring frequent blood samples. This segment's growth is driven by the increasing demand for accurate and non-invasive glucose monitoring solutions, which improve diabetes management and enhance the quality of life for diabetic pets.

Veterinary insulin is a critical component of diabetes management for pets. This segment includes various insulin formulations specifically designed for animals, such as porcine and recombinant human insulin. Veterinary insulin products are tailored to meet the unique physiological needs of pets, ensuring safe and effective diabetes control. The increasing prevalence of diabetes among pets has led to a growing demand for veterinary insulin, driving the market for this segment. Additionally, ongoing research and development efforts are focused on creating more effective and longer-lasting in

The Dogglietin market for patients with Type 2 Diabetes has emerged as a pivotal segment in the diabetes treatment landscape, driven by a growing need for effective glucose-lowering therapies that enhance patients' quality of life. This innovative medication, a member of the Class of drugs known as DPP-4 inhibitors,

Snapshot img

Insulin Pump Market Size 2024-2028

The insulin pump market size is forecast to increase by USD 9.43 billion at a CAGR of 21.81% between 2023 and 2028. The market is witnessing robust growth due to the escalating global diabetes prevalence, favorable government initiatives geared towards diabetes treatment, and the availability of comprehensive diabetes self-management education programs. This expansion is primarily driven by the increasing demand for innovative solutions, technological advancements, and evolving consumer preferences. Key market dynamics include the transition towards more efficient systems, improved accessibility, and higher industry standards. In response, industry players are adapting their strategies to align with these trends, prioritizing sustainability and operational efficiency to maintain a competitive edge. As the market continues to evolve, these factors are shaping its trajectory, ensuring long-term growth. The industry's focus on delivering advanced solutions is expanding its scope, addressing the growing demand for sophisticated diabetes management tools. The global diabetes burden is on the rise, necessitating the development of more effective and accessible treatment options. Government initiatives aimed at improving diabetes care and increasing public awareness are further fueling market growth.

What will be the size of the market during the forecast period?

Request Free Sample

Insulin Pump Market Segmentation

The insulin pump market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

Type

  Tethered pumps
  Patch pumps


Distribution Channel

  Offline
  Online


Geography

  North America

    US


  Europe

    Germany
    UK


  Asia

    China
    Japan


  Rest of World (ROW)

Which is the largest segment driving market growth?

The tethered pumps segment is estimated to witness significant growth during the forecast period.

Insulin pumps are computerized devices designed to deliver insulin to diabetic persons, both those with Type 1 and Type 2 diabetes, in a more controlled and efficient manner than traditional insulin injections. These devices have gained popularity due to their ability to provide automatic insulin administration based on real-time glucose monitoring and advanced features like Artificial Intelligence (AI) and Machine Learning (ML) algorithms. Tethered insulin pumps, which use a flexible tube connecting the pump to the cannula, are commonly used. Notable examples include the Accu-Chek Spirit Combo, which integrates a smartphone for sugar monitoring, diagnosis, and bolus calculation. The market for insulin pumps is expanding due to the increasing incidence of diabetes, aging population, unhealthy lifestyles, and risk factors like obesity, sedentary lifestyle, and diseases such as cataract, glaucoma, hypertension, and diabetes indications.

Insulin pumps are available through retail and hospital pharmacies, home infusion treatments, and electronic versions. Closed-loop pumps, also known as artificial pancreas systems, are the latest advancement in insulin pump technology. The market for insulin pumps is significant in developed nations, with a growing focus on tubeless insulin pumps and AI-enabled pumps to improve accuracy and convenience for diabetic patients.

Get a glance at the market share of various regions. Download the PDF Sample

The Tethered pumps segment was valued at USD 2.38 billion in 2018 and showed a gradual increase during the forecast period.

Which region is leading the market?

North America is estimated to contribute 58% to the growth of the global market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.The market in North America is experiencing growth due to the rising prevalence of type 1 and type 2 diabetes and technological advancements in healthcare. According to the Centers for Disease Control and Prevention (CDC), over 130 million adults In the US have diabetes or prediabetes, with type 2 diabetes accounting for 90-95% of cases. Factors contributing to this increase include an aging population, sedentary lifestyles, and obesity. The CDC reports that new diabetes diagnoses are equal among women and men aged 45-64 years. Insulin pumps, computerized devices that deliver insulin automatically, are becoming increasingly popular for diabetes management. These pumps can be integrated with AI and machine learning technologies, smartphones, and continuous sugar monitoring systems for closed-loop insulin delivery.

Additionally, AI-enabled pumps are being developed for type 2 diabet

The Diabetes Treatment market has emerged as a critical segment within the global healthcare landscape, primarily driven by the rising prevalence of diabetes and the increasing awareness surrounding effective management and treatment options. As of recent estimates, the market is valued in billions, reflecting a sig

The entire market for microvascular complications of diabetes (MCD) – diabetic nephropathy, retinopathy, and neuropathy – is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors. Read More

The global diabetes software market is experiencing robust growth, driven by the increasing prevalence of diabetes worldwide and the rising adoption of digital health solutions for disease management. The market, estimated at $2.5 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 15% from 2025 to 2033, reaching an estimated market value of $7 billion by 2033. This expansion is fueled by several key factors. The increasing availability of sophisticated software solutions designed for both type 1 and type 2 diabetes management, offering features like blood glucose monitoring, insulin dosage calculation, and data analysis, is a significant driver. Furthermore, the rising penetration of smartphones and tablets, coupled with improved internet connectivity, creates a conducive environment for widespread adoption of web-based and app-based diabetes management software. The integration of these applications with wearable health trackers further enhances their appeal, promoting proactive health management and improved patient outcomes. Market segmentation reveals a strong demand across various platforms (smartphones, tablets, web-based) and diabetes types, with significant growth anticipated in both type 1 and type 2 diabetes software segments. Competition among established players like Glooko, Accu-Chek (Roche), and Dexcom, alongside emerging innovative companies, is driving innovation and affordability. Geographical analysis indicates strong growth potential in North America and Europe, followed by significant expansion in the Asia-Pacific region due to its burgeoning diabetic population and growing healthcare infrastructure. Despite the positive growth trajectory, challenges remain. Concerns about data privacy and security, along with the need for robust regulatory frameworks to ensure the accuracy and safety of these applications, could pose some limitations to market expansion. Additionally, disparities in healthcare access and digital literacy across different regions might hinder the universal adoption of diabetes software. Addressing these challenges through collaborative efforts between developers, regulatory bodies, and healthcare providers is crucial for the sustainable growth and broader impact of diabetes software in improving diabetes management globally.

The Diabetes Medical Devices market has rapidly evolved in response to the increasing prevalence of diabetes worldwide, impacting millions of individuals and healthcare systems. As of recent reports, the global market is valued at approximately USD 17 billion and is projected to reach over USD 22 billion by 2025, sh

POC Diabetes Analyzer Market Outlook

The global point-of-care (POC) diabetes analyzer market size was valued at approximately $1.5 billion in 2023, and it is projected to reach $3.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 10.5% during the forecast period. This market's growth is driven by the increasing prevalence of diabetes, advancements in diagnostic technologies, and rising demand for rapid, accurate, and convenient diagnostic tools.

One of the significant growth factors in the POC diabetes analyzer market is the escalating prevalence of diabetes across the globe. According to the International Diabetes Federation (IDF), the number of adults with diabetes is expected to rise significantly, reaching over 700 million by 2045. This alarming increase is primarily due to sedentary lifestyles, unhealthy eating habits, and the growing incidence of obesity. Consequently, the demand for efficient and user-friendly diagnostic tools such as POC diabetes analyzers is expected to surge, driving the market's expansion.

Another critical driver is the advancement in diagnostic technologies. Innovations in biosensor technology have significantly enhanced the accuracy, speed, and ease of use of POC diabetes analyzers. Electrochemical and optical biosensors, in particular, have enabled the development of compact, portable devices that provide real-time blood glucose monitoring. These technological advancements are crucial in managing diabetes effectively, fostering market growth.

The increasing emphasis on home-based healthcare is also contributing to the market's growth. With the rise in the elderly population and the growing need for continuous monitoring and management of chronic conditions like diabetes, there has been a significant shift towards home care settings. POC diabetes analyzers, being portable and easy to use, are well-suited for such environments, thereby boosting their adoption among patients and caregivers.

Regionally, North America is expected to hold the largest market share due to the high prevalence of diabetes, advanced healthcare infrastructure, and the presence of major market players. However, the Asia Pacific region is anticipated to witness the highest growth rate during the forecast period, driven by the increasing diabetes population, economic development, and rising healthcare expenditure in countries like China and India.

Product Type Analysis

The product type segment of the POC diabetes analyzer market is categorized into handheld devices and bench-top devices. Handheld devices are anticipated to dominate the market owing to their portability, ease of use, and increasing preference for home-based care. These devices allow users to monitor their blood glucose levels conveniently, making them highly popular among patients who require regular monitoring.

Handheld devices are particularly beneficial for patients who need to check their blood glucose levels multiple times a day. These devices are designed to be user-friendly, requiring minimal training to operate, which is essential for elderly patients and those without medical backgrounds. The convenience offered by handheld devices is a significant factor driving their widespread adoption.

Bench-top devices, on the other hand, are typically used in clinical settings such as hospitals, diagnostic centers, and clinics. These devices are generally larger and more sophisticated, providing comprehensive analysis and higher accuracy. They are preferred for their capability to handle a higher volume of tests and for use in more controlled environments where professional healthcare providers are available.

The continuous development of both handheld and bench-top devices is expected to propel the market further. Manufacturers are focusing on enhancing the features of these devices, such as integrating wireless connectivity, data storage, and compatibility with various health management platforms. These advancements are likely to appeal to both healthcare professionals and patients, contributing to the market's growth.

Report Scope

Attributes	Details
Report Title <